Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.

Slides:

Advertisements

Similar presentations

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Advertisements

Erik Ames, Salif Harouna, Colin Meyer, Lisbeth A. Welniak, William J

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells Faith M. Young, Andrew.

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation

Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell.

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

Identification of Stem Cell Transcriptional Programs Normally Expressed in Embryonic and Neural Stem Cells in Alloreactive CD8+ T Cells Mediating Graft-versus-Host.

Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Weiqing Jing,

by Dennis Adeegbe, Robert B. Levy, and Thomas R. Malek

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad,

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

by Norman Nausch, Ioanna E

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease by Tomomi Toubai, Yaping Sun, Isao Tawara, Ann Friedman,

Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation Lucrezia Colonna, Mareike.

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.

Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice Chien-Chun Steven Pai,

Evelyn C. Nieves, Tomomi Toubai, Daniel C

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal Patricia A. Taylor,

Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host.

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses William H.D. Hallett, Erik Ames, Maite.

An Essential Role for IFN-γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation Wannee Asavaroengchai,

Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT Alwi M. Shatry, Derry C. Roopenian, Robert B.

Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

Cytolytic Pathways Used by Effector Cells Derived from Recipient Naive and Memory T Cells and Natural Killer Cells in Resistance to Allogeneic Hematopoietic.

Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation Jeffery J. Auletta,

Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells

T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning Gabor Varadi,

Volume 10, Issue 5, Pages (May 1999)

Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous- BMT Improves the Survival of Leukemia-Challenged Mice Jenny Zilberberg,

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells Christian Scheffold, Yolanda C. Scheffold,

Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation Jian-Ming Li, Edmund K.

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects Jeffrey S. Moyer, Gabriel.

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host.

Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G

Cord Blood Nucleated Cells Induce Delayed T Cell Alloreactivity

Specific donor Vβ-associated CD4+ T-cell responses correlate with severe acute graft- versus-host disease directed to multiple minor histocompatibility.

Volume 17, Issue 5, Pages (November 2002)

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution Maria Gendelman, Maryam Yassai,

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.

Presentation transcript:

Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts without Participation of Perforin, Fas Ligand, and the Simultaneous Inhibition of 3 Tumor Necrosis Factor Family Effector Pathways Zachary Zimmerman, Alwi Shatry, Vadim Deyev, Eckhard Podack, Michele Mammolenti, Bruce R. Blazar, Hideo Yagita, Robert B. Levy Biology of Blood and Marrow Transplantation Volume 11, Issue 8, Pages 576-586 (August 2005) DOI: 10.1016/j.bbmt.2005.05.006 Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 B6-wt (H2b) recipients were sensitized to C3H.SW (H2b) alloantigens and administered anti-CD8 mAb (see “Materials and Methods”) to deplete host CD8+ T cells before transplantation. Controls were treated with phosphate-buffered saline. After 9.0 Gy of total body irradiation, B6-wt recipients underwent transplantation with 1 × 107 C3H.SW TCD BM cells. Unsensitized recipients also underwent transplantation as controls. At 5 days after transplantation, recipient splenocytes were harvested and assayed for CFU-granulocyte macrophage (CFU-GM) (A) or CFU-HPP (B). Data represent CFUs per spleen (mean ± SEM). Statistical differences between groups were determined by analysis of variance with the Tukey multiple comparison test. Biology of Blood and Marrow Transplantation 2005 11, 576-586DOI: (10.1016/j.bbmt.2005.05.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 A, Immunodominant (H60) MiHA-specific CD8 cells express a memory cell phenotype. B6-wt mice were sensitized with 3 × 107 BALB.B cells intraperitoneally and 4 weeks later were boosted with 2 × 107 cells. Peripheral blood leukocytes gated on CD8+ H60+ cells were analyzed for the presence of tetramer staining (H60 phycoerythrin [PE]) and expression of CD44 and Ly 6C. B, Resistance to MiHA-mismatched donor marrow grafts in B6BALB.B recipients. B6-wt mice containing anti-BALB.B memory cells were irradiated with 9.0 Gy of total body irradiation (day −1) and then underwent transplantation with 1 × 107 TCD BALB.B cells. Within 1 week after BMT, splenic CFU-IL-3 assays were performed. Data are expressed as percentage of control CFU-IL-3, where control is CFU numbers in B6naive recipients. Biology of Blood and Marrow Transplantation 2005 11, 576-586DOI: (10.1016/j.bbmt.2005.05.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 B6 cytotoxically normal and deficient (perforin/FasL) recipients sensitized to allogeneic MiHA exhibit indistinguishable resistance to donor CFU-IL-3 and CFU-HPP 48 hours after transplantation. After 9.0 Gy of total body irradiation, B6-wt or B6-cdd recipients underwent transplantation with 1 × 107 TCD BM cells from MiHA-mismatched C3H.SW donors. Recipients were either unsensitized or sensitized to donor antigens 1 month before transplantation. Forty-eight hours after transplantation, recipient splenocytes were harvested and assayed for the presence of CFU-granulocyte macrophage (CFU-GM) (A) or CFU-HPP (B). Data represent CFUs per spleen (mean ± SEM). Statistical differences between groups were determined by analysis of variance with the Tukey multiple comparison test. Biology of Blood and Marrow Transplantation 2005 11, 576-586DOI: (10.1016/j.bbmt.2005.05.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 A and B, B6-cdd mice sensitized to donor C3H.SW alloantigens underwent transplantation with 1 × 107 TCD BM cells from allogeneic MHC-matched/MiHA-disparate donors (C3H.SW) or B6-gfp as a syngeneic control transplantation. On days −1 and 0 before BMT, recipients received no antibody, 250 μg of anti-TRAIL, or 250 μg of both anti-TRAIL and anti-TWEAK blocking mAbs. On day 5 after transplantation, recipient spleens were harvested and cultured for the presence of CFU-IL-3 (A) or CFU-HPP (B). Data represent the number of CFUs (mean ± SD; n = 3–4 per group). C, 2PK3/mTRAIL or 2PK3 L cells were incubated with 51Cr-labeled L929 target cells at varying effector-target ratios for 4 hours. Anti-TRAIL 10 μg/mL or an isotype control antibody (IgG2a) was added to each well. Data represent mean specific lysis from triplicate cultures. Biology of Blood and Marrow Transplantation 2005 11, 576-586DOI: (10.1016/j.bbmt.2005.05.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 A and B, B6-cdd mice were sensitized to donor alloantigens (C3H.SW) and then underwent transplantation with 1 × 107 TCD BM cells from allogeneic donors (C3H.SW) or B6-gfp as a syngeneic control. On days −1 and 0 before transplantation, recipients received no antibody, 250 μg of anti-TRAIL, 250 μg of both anti-TRAIL and anti-TWEAK, or 250 μg each of anti-TRAIL, anti-TWEAK, and anti-TL1A (L4G6) blocking mAbs. On day 5 after transplantation, recipient splenocytes were harvested and cultured for the presence of CFU-IL-3 (A) or CFU-HPP (B). Data represent the number of CFU s (mean ± SD; n = 3–4 per group). C, TL1A-containing supernatant was tested against 51Cr-labeled EL4-DR3 and was shown to effect lysis in a 4-hour release assay. Varying amounts of TL1A supernatant were then mixed with L4G6- and L3A10-containing supernatants in a 1:1 volume ratio and preincubated for 30 minutes before addition to these target cells. Data represent mean specific lysis from triplicate cultures. Biology of Blood and Marrow Transplantation 2005 11, 576-586DOI: (10.1016/j.bbmt.2005.05.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions